Global

May 04, 2016
The dilemma continues: Which medicines should Europe's health systems pay for – and how much should they pay?
May 02, 2016
By
As companies look to raise capital, selling and then leasing back real estate is a tempting option and one that other industries are utilizing, writes Karen Williamson.
Apr 04, 2016
Reflector sees both altruism and self-interest in European thinking on neglected diseases.
Mar 06, 2016
Pharmaceutical Executive
A new study spells out the many drug pricing problems in Europe just fine, but fails to address a central access issue.
Mar 01, 2016
Bruno Villetelle discusses how Japanese companies like Takeda have begun to digitize in order to care for the country's aging population.
Feb 25, 2016
As a European politician attacks abuses of the orphan drug scheme, an EU report extols its virtues. Reflector asks: in Europe, does the right hand know what the left hand is doing?
Feb 18, 2016
By
Arvind Mani and Sherry O' Quinn outline the prevalence of private payer PLAs in Canada.
Feb 17, 2016
Following the consultation on the future of England's Cancer Drug Fund, Leela Barham reviews what the stakeholders are thinking.
Feb 01, 2016
Pharmaceutical Executive
What the drug industry stands to gain — or lose — from the unthinkable: Britain departing the European Union.
Jan 25, 2016
Kevin E. Noonan asks, what do the biosimilars provisions of the Trans-Pacific Partnership portend for global biologic drug development?
native1_300x100
подробнее

www.dopingman.com.ua/tabletirovannyie-steroidyi/stanozolol/strombafort-200-tab.html

там
lorem ipsum